Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects (Q37062092)

18 August 2017

1 reference

title

Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects (English)

1 reference

glucocorticoid-induced osteoporosis

18 August 2017

0 references

1 reference

3

Ernesto Canalis

0 references

John P. Bilezikian

series ordinal

4

object named as

John P Bilezikian

1 reference

18 August 2017

2

Andrea Giustina

1 reference

18 August 2017

Gherardo Mazziotti

1

1 reference

PubMed ID

18209880

18 August 2017

Ernesto Canalis

series ordinal

3

1 reference

18 August 2017

1 November 2007

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

18 August 2017

1 reference

18 August 2017

51

1 reference

18 August 2017

8

1 reference

18 August 2017

1404-1412

1 reference

Glucocorticoid-induced osteoporosis: an update

18 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Perspectives on glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Bone morphogenetic proteins and their antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Cortisol Increases Interstitial Collagenase Expression in Osteoblasts by Post-transcriptional Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Growth hormone in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Growth hormone changes bone geometry and body composition in patients with juvenile idiopathic arthritis requiring glucocorticoid treatment: a controlled study using peripheral quantitative computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoporosis associated with excess glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoporosis after solid organ and bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Fracture risk associated with systemic and topical corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Use of inhaled corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Inhaled corticosteroids and hip fracture: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Effects of inhaled glucocorticoids on bone density in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Skeletal morbidity in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

An association between respiratory function and bone mineral density in women from the general community: a cross sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The risk of osteoporosis in Caucasian men and women with obstructive airways disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Practice patterns in patients at risk for glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoporosis in men: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Is bone mineral density predictive of fracture risk reduction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Clinical utility of microarchitecture measurements of trabecular bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Ascertainment of risk factors for osteoporosis: comparison of interview data with medical record review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Recognizing and reporting osteoporotic vertebral fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Unprincipled QALYs: a response to Cubbon

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The Vitamin D requirement in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Osteoblastic cells regulate the haematopoietic stem cell niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Bone Loss and Inhaled Glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case?control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid-Induced Osteoporosis: A Meta-Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302007000800028

10.1590/S0004-27302007000800028

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18209880